Early trials of the Oxford University COVID-19 vaccine are showing some success against coronavirus. Scientists at the University say early results prompted an immune response in over 1000 volunteers who were given the dose.
The COVID-19 vaccine trials’ protective response lasted for about two months.
The vaccine called AZD1222 is jointly developed by British-Swedish company AstraZeneca and UK’s Oxford University.
According to the results published in The Lancet medical journal on Monday, the vaccine based on a chimpanzee adenovirus called ChAdOx1 triggered antibody and T-cell immune responses.
The phase I/II trial done on 1077 healthy participants, aged between 18 and 55 years, drawn from the UK suggests that the vaccine did not appear to cause any serious side effects on the volunteers.
This way, the body’s immune system can learn how to attack the virus by producing neutralizing antibodies, the molecules responsible for blocking the virus infection.
A ready vaccine not yet
However, WHO warns countries from dropping the guard and says there is a long way to go.
At least six months timeline is needed to determine the safety and efficacy of the virus before mass production is initiated.
The combined phase II/III trials to evaluate the vaccine’s effectiveness involves about 10,000 people from the UK, South Africa, and Brazil. Another trial involving 30,000 participants is planned to begin in the US.
For a vaccine to be effective, it must prove useful for elderly people and people with pre-existing conditions.
The vaccine should also be effective for at least six months before another dose is acquired.
However, widespread vaccination could be available, at the earliest, next year even if everything goes to plan.